Page 102 - ITPS-8-3

INNOSC Theranostics and
Pharmacological Sciences Biomarkers for early heart risks in pre-eclampsia

vascular endothelial dysfunction and increase the risk of pathways and potential therapeutic targets can be
CVDs. For risk assessment and early detection, reliable revealed by identifying and quantifying proteins in
biomarkers associated with these processes must be biological materials.
found. Tumor necrosis factor-alpha, interleukins (IL-6, Together, these biomarkers increase the precision of CV
IL-8), and hs-CRP are important inflammatory indicators risk assessment in pre-eclampsia, enabling personalized
that reveal status about the chronic inflammatory milieu treatment and early intervention. Their integration into
of pre-eclampsia. At the same time, increased levels of clinical practice has the potential to revolutionize maternal
21
oxidative stress indicators such as malondialdehyde, nitric healthcare by improving diagnosis accuracy and promoting
oxide, endothelin-1, ADMA and 8-isoprostane, along with creative preventative strategies for CV problems in pre-
reduced antioxidant defenses, such as glutathione levels, eclampsia.
indicate oxidative burden in affected individuals. 22
The assessment of CV risk in pre-eclampsia could be 4. From association to action: Translating
revolutionized by predictive algorithms, advanced imaging, knowledge into prevention and risk
and innovative diagnostic techniques that utilize these assessment
indicators. By integrating these biomarker profiles with Pre-eclampsia is becoming more widely acknowledged as
clinical data, healthcare providers can implement targeted
interventions that will ultimately enhance maternal CV a risk factor for women’s long-term CV health. A thorough
health outcomes and reduce long-term problems. framework for risk assessment and prevention is necessary
to close the gap between this association and workable
Monitoring indicators of endothelial dysfunction solutions. To convert scientific discoveries into significant
facilitates the assessment of the long-term CV risks in public health results, this framework should include risk
affected women. These biomarkers may be used to predict categorization, preventative measures, and healthcare
CV risks following childbirth and to shed light on systemic integration.
inflammation. Together, these biomarkers demonstrate the (i) Risk stratifications. Utilizing clinical and biochemical
complex relationship between CV risks and pre-eclampsia, indicators identified during pregnancy is essential for
opening the door to focused prevention measures. identifying patients at increased CV risk after pre-
eclampsia. Future risk can be inferred from markers
24
3.5. Exosomal, epigenetic, and proteomic including dysregulated lipid profiles, proteinuria, and
biomarkers high blood pressure. Categorization into high- and
Exosomal, epigenetic, and proteomic biomarkers have low-risk groups allows for customized post-partum
become novel approaches to address this problem. Cells treatment. Women who have severe or recurring pre-
release exosomes, which are nanovesicles containing eclampsia, for example, may be deemed high-risk and
bioactive substances, such as lipids, proteins, and RNA. require close observation. Risk prediction models
25
These molecules reflect physiological parameters and offer can be further improved by emerging biomarkers,
information on pathological alterations. Placenta-derived such as angiogenic factors, such as PlGF and sFlt-1.
exosomes contain proteins, lipids, and microRNAs that Predictive analytics and electronic health records can
23
reveal the placenta’s health and dysfunction. Past research expedite this stratification procedure, guaranteeing
highlights the role that epigenetic changes play in the CV the early and methodical identification of high-risk
risks linked to pre-eclampsia: individuals.
(i) miRNAs or microRNAs. Circulating and specific (ii) Preventative interventions. Specific prophylactic
miRNAs, including miR-210 and miR-155, control actions can reduce long-term CV morbidity in high-
immunological and angiogenic pathways and serve risk women. The cornerstone tactics are lifestyle
as non-invasive biomarkers for pathophysiology, changes, such as diet adjustments, exercise, and
pre-eclampsia, disease development, and CV risk stress reduction. In accordance with individual risk
prediction. Examples of epigenetic biomarkers that profiles, pharmacological therapy with medications
shed light on gene-environment interactions that raise such as statins or antihypertensives can be used
the risk of pre-eclampsia development include DNA to treat chronic dyslipidemia or hypertension.
methylation and histone modifications. Establishing routine CV screenings after pregnancy
(ii) Proteomic signatures. By analyzing plasma is also essential. Early identification of endothelial
26
proteomically, distinct protein signatures associated dysfunction, subclinical atherosclerosis, and other
with endothelial dysfunction and CV risk have been risk factors for CVDs should be the main goal of such
found. Across the proteomics approach, dysregulated examinations. Effective implementation of evidence-

Volume 8 Issue 3 (2025) 96 doi: 10.36922/itps.7839